Parallel Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $234K | Buy |
1,776
+195
| +12% | +$25.9K | ﹤0.01% | 1083 |
|
|
2025
Q4 | $224K | Sell |
1,581
-51
| -3% | -$7.39K | ﹤0.01% | 1039 |
|
|
2025
Q3 | $229K | Buy |
1,632
+41
| +3% | +$5.55K | ﹤0.01% | 992 |
|
|
2025
Q2 | $200K | Buy |
1,591
+212
| +15% | +$24.3K | ﹤0.01% | 1012 |
|
|
2025
Q1 | $153K | Sell |
1,379
-632
| -31% | -$80.1K | ﹤0.01% | 1073 |
|
|
2024
Q4 | $275K | Buy |
2,011
+172
| +9% | +$21.3K | 0.01% | 799 |
|
|
2024
Q3 | $212K | Buy |
1,839
+140
| +8% | +$19.2K | 0.01% | 899 |
|
|
2024
Q2 | $234K | Buy |
1,699
+12
| +0.7% | +$1.65K | 0.01% | 808 |
|
|
2024
Q1 | $233K | Buy |
1,687
+151
| +10% | +$20.6K | 0.01% | 806 |
|
|
2023
Q4 | $202K | Sell |
1,536
-308
| -17% | -$35.5K | 0.01% | 798 |
|
|
2023
Q3 | $207K | Buy |
1,844
+713
| +63% | +$75.1K | 0.01% | 774 |
|
|
2023
Q2 | $107K | Buy |
1,131
+88
| +8% | +$8.6K | ﹤0.01% | 1040 |
|
|
2023
Q1 | $106K | Buy |
1,043
+79
| +8% | +$8.22K | ﹤0.01% | 1030 |
|
|
2022
Q4 | $115K | Buy |
964
+123
| +15% | +$14.4K | 0.01% | 935 |
|
|
2022
Q3 | $89K | Buy |
841
+256
| +44% | +$26K | ﹤0.01% | 1015 |
|
|
2022
Q2 | $57K | Sell |
585
-54
| -8% | -$4.98K | ﹤0.01% | 1188 |
|
|
2022
Q1 | $59K | Buy |
639
+175
| +38% | +$14.8K | ﹤0.01% | 1216 |
|
|
2021
Q4 | $40K | Buy |
464
+1
| +0.2% | +$92 | ﹤0.01% | 1443 |
|
|
2021
Q3 | $44K | Buy |
463
+261
| +129% | +$24.7K | ﹤0.01% | 1333 |
|
|
2021
Q2 | $20K | Buy |
202
+27
| +15% | +$2.59K | ﹤0.01% | 1686 |
|
|
2021
Q1 | $17K | Buy |
175
+3
| +2% | +$315 | ﹤0.01% | 1674 |
|
|
2020
Q4 | $16K | Sell |
172
-1
| -0.6% | -$97 | ﹤0.01% | 1589 |
|
|
2020
Q3 | $17K | Buy |
173
+29
| +20% | +$3.35K | ﹤0.01% | 1515 |
|
|
2020
Q2 | $17K | Sell |
144
-19
| -12% | -$2.1K | ﹤0.01% | 1482 |
|
|
2020
Q1 | $14K | Buy |
163
+4
| +3% | +$391 | ﹤0.01% | 1469 |
|
|
2019
Q4 | $17K | Hold |
159
| – | – | ﹤0.01% | 1487 |
|
|
2019
Q3 | $14K | Buy |
159
+31
| +24% | +$2.9K | ﹤0.01% | 1531 |
|
|
2019
Q2 | $11K | Hold |
128
| – | – | ﹤0.01% | 1556 |
|
|
2019
Q1 | $11K | Hold |
128
| – | – | ﹤0.01% | 1494 |
|
|
2018
Q4 | $9K | Sell |
128
-6
| -4% | -$575 | ﹤0.01% | 1378 |
|
|
2018
Q3 | $16K | Hold |
134
| – | – | ﹤0.01% | 1246 |
|
|
2018
Q2 | $13K | Buy |
134
+36
| +37% | +$3.22K | ﹤0.01% | 1232 |
|
|
2018
Q1 | $8K | Hold |
98
| – | – | ﹤0.01% | 1369 |
|
|
2017
Q4 | $8K | Hold |
98
| – | – | ﹤0.01% | 1383 |
|
|
2017
Q3 | $7K | Buy |
98
+9
| +10% | +$475 | ﹤0.01% | 1435 |
|
|
2017
Q2 | $4K | Hold |
89
| – | – | ﹤0.01% | 1682 |
|
|
2017
Q1 | $5K | Buy |
89
+9
| +11% | +$386 | ﹤0.01% | 1504 |
|
|
2016
Q4 | $3K | Buy |
+80
| New | +$3.62K | ﹤0.01% | 1540 |
|
Other funds holding NBIX
VPM
VCM
Parallel Advisors's NBIX Position: Q1 2026 in Review
Parallel Advisors increased its Neurocrine Biosciences (NBIX) stake by 12% in Q1 2026, buying an estimated $25.9K and bringing the position to 1,776 shares worth $234K. The position accounts for ﹤0.01% of the portfolio, ranked #1083.
Parallel Advisors first reported a position in NBIX in Q4 2016 and has held it in 38 quarters since. The position peaked at $275K in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Parallel Advisors held 1,776 shares of Neurocrine Biosciences worth $234K as of Q1 2026.
- Parallel Advisors bought 195 Neurocrine Biosciences shares in Q1 2026, an estimated $25.9K.
- Neurocrine Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #1083 holding.
- Parallel Advisors first reported a position in Neurocrine Biosciences in Q4 2016 and has held it in 38 quarters since.
- Parallel Advisors's Neurocrine Biosciences position peaked at $275K in Q4 2024.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.